OPKO Health (Ireland)

Ireland · 459 open jobs on MadeVisa

Open roles at OPKO Health (Ireland), straight from its careers page, with hiring activity and the share of applicants who got a reply.

Open jobs at OPKO Health (Ireland)

• OPKO Health Reports 2022 Second Quarter Business Highlights and Financial Results
• Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms
• OPKO Health Announces Leadership Changes for BioReference Laboratories
• RAYALDEE® Launched in Germany by OPKO Health’s Licensee, VFMCRP
• OPKO Health to Report Fourth Quarter 2021 Financial Results on February 24, 2022
• Pfizer and OPKO’s Once-Weekly NGENLATM (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency
• OPKO Health to Report Third Quarter 2022 Financial Results on November 8, 2022
• OPKO Health to Present at the 2022 Jefferies Healthcare Conference
• OPKO Health Reports Third Quarter 2022 Business Highlights and Financial Results
• OPKO Health to Report Fourth Quarter 2022 Financial Results on February 23, 2023
• OPKO Health to Report Second Quarter 2022 Financial Results on August 4, 2022
• Major League Soccer Renews with BioReference Laboratories as COVID-19 Testing Provider for Second Year
• OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases
• OPKO Health to Report First Quarter 2022 Financial Results on May 9, 2022
• OPKO Health Reports 2022 First Quarter Business Highlights and Financial Results
• Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency
• OPKO Health Reports 2021 Fourth Quarter Business Highlights and Financial Results
• OPKO Health to Present at the 41st Annual J.P. Morgan Healthcare Conference
• OPKO Announces Dismissal of PROLOR Biotech, Inc. Class Action Lawsuit
• OPKO Health Names Dr. Gregory Henderson President of Bio-Reference Laboratories
• OPKO Announces 4Kscore® Abstracts at the 2015 American Urological Association (AUA) Annual Meeting
• OPKO Announces Positive Interim Six-Month Lagova™ (hGH-CTP) Phase 2 Data in Pediatric Growth Hormone Deficiency Disorder
• OPKO’s GeneDx Study Demonstrates Whole Exome Sequencing Usefulness In Diagnosing Rare Disorders
• OPKO Adds to Growing Technology Portfolio Through Strategic Investment in Biotechnology Company Engaged in the Development of a New Generation of Antibodies
• OPKO Submits IND for Rayaldee™ as Adjunctive Cancer Therapy
• OPKO Health to Present at the Oppenheimer 26th Annual Healthcare Conference
• OPKO Announces Fourth Quarter and Full Year 2013 Results
• OPKO and Bio-Reference Laboratories To Hold Joint Conference Call to Discuss Merger
• OPKO Health Provides Update on hGH-CTP Clinical Programs
• OPKO Completes Patient Recruitment in Second Phase 3 Trial of RayaldyTM
• OPKO Lab Receives Accreditation From College of American Pathologists
• OPKO Health Announces Global License Agreement for the Discovery of Novel Antimicrobials
• OPKO Health’s GeneDx Announces Participation in Illumina’s iHope Program on International Rare Disease Day
• OPKO Investee SciVac Announces the Completion of Transaction with Levon Resources
• OPKO Announces Launch of 4Kscore Test for Prostate Cancer
• OPKO Presents Additional Data on RAYALDEE® at ENDO 2016 — Expo Hall
• OPKO Announces Third Quarter Financial and Operating Results
• Transition Therapeutics Shareholders Approve Acquisition by OPKO Health
• OPKO Licensee TESARO Receives FDA Approval for VARUBI™ (rolapitant)
• OPKO Health Announces Move to NASDAQ Stock Market